Evidence map›Paper›PMID 37325963›Full record

ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2023

Synergistic Strategies to Accelerate the Development of Function-Promoting Therapies: Lessons From Operation Warp Speed and Oncology Drug Development.

Rosaly Correa-de Araujo, William J Evans, Roger A Fielding, Venkatesh Krishnan, Robert H Carter, James Appleby, Jack Guralnik, Lloyd B Klickstein, Peter Marks, Alison A Moore and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Operation Warp Speed offers a roadmap for improving the efficiency of bench to bedside medical advances.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Rosaly Correa-de AraujoNational Institute on Aging, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland, USA.
William J EvansDepartment of Nutritional Science and Toxicology, University of California at Berkely, Berkely, California, USA.
Roger A FieldingNutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, USA.
Venkatesh KrishnanEli Lilly, Inc., Indianapolis, Indiana, USA.
Robert H CarterNational Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland, USA.ORCID 0000-0001-7300-6700
James ApplebyGerontological Society of America (GSA), Washington, District of Columbia, USA.
Jack GuralnikDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Lloyd B KlicksteinVersanis Bio, Inc., Oakland, California, USA.
Peter MarksU.S. Food and Drug Administration (FDA), U.S. Department of Health and Human Services, Silver Spring, Maryland, USA.ORCID 0000-0001-5619-4404
Alison A MooreDepartment of Medicine, University of California, San Diego, San Diego, California, USA.
Sue PeschinAlliance for Aging Research, Aging in Motion, Washington, District of Columbia, USA.
Shalender BhasinResearch Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-3982-6200
National Institutes of Health · USAlliance for Aging Research · USBrigham and Women's Hospital · USEli Lilly (United States) · USGerontological Society of America · USTufts University · USUnited States Department of Health and Human Services · USUniversity of California San Diego · USUniversity of Maryland, Baltimore · US

Funding

University of Maryland Claude D. Pepper Older Americans Independence Center (UM-OAIC)P30AG028747 · NIA · UNIVERSITY OF MARYLAND BALTIMORE · PI Stephen L. Seliger · 2006 to 2026
$28.9M
Core B - Pilot StudiesP30AG048785 · NIA · BRANDEIS UNIVERSITY · PI LACHMAN, MARGIE E · 2014 to 2023
$4.5M
FDA HHSNIAMS NIH HHSNIA NIH HHS P30 AG028747NIA NIH HHS P30 AG048785NIH HHS
6 · The paper itself

Abstract

backgroundFunctional limitations and physical disabilities associated with aging and chronic disease are major concerns for human societies and expeditious development of function-promoting therapies is a public health priority.

methodsExpert panel discussion.

resultsThe remarkable success of Operation Warp Speed for the rapid development of COVID-19 vaccines, COVID-19 therapeutics, and of oncology drug development programs over the past decade have taught us that complex public health problems such as the development of function-promoting therapies will require collaboration among many stakeholders, including academic investigators, the National Institutes of Health, professional societies, patients and patient advocacy organizations, the pharmaceutical and biotechnology industry, and the U.S. Food and Drug Administration.

conclusionsThere was agreement that the success of well designed, adequately powered clinical trials will require careful definitions of indication/s, study population, and patient-important endpoints that can be reliably measured using validated instruments, commensurate resource allocation, and versatile organizational structures such as those used in Operation Warp Speed.

Indexed as

COVID-19COVID-19 VaccinesDrug DevelopmentHumansNational Institutes of Health (U.S.)United StatesCOVID-19 VaccinesAge-related skeletal muscle dysfunctionFunction-promoting therapiesMobility-disabilitySarcopeniaSkeletal muscle function deficit

Identifiers

PMID37325963
PMCPMC10272982
OpenAlexW4380869395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.